RBC Capital Reiterates Outperform on Evolent Health, Maintains $44 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Sean Dodge reiterates an Outperform rating on Evolent Health (NYSE:EVH) and maintains a $44 price target.
May 24, 2023 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evolent Health (NYSE:EVH) receives an Outperform rating from RBC Capital analyst Sean Dodge, with a maintained price target of $44.
RBC Capital's reiterated Outperform rating and maintained price target of $44 for Evolent Health (NYSE:EVH) indicates a positive outlook for the stock. This news is likely to have a short-term positive impact on the stock price, as it shows confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100